Current News

Contact | Print version | Send article | RSS feed

TopoTarget completes the capital increase and the acquisition of Apoxis SA

29 Jun 2007 - TopoTarget A/S announced the completion of the acquisition of Apoxis SA with 3,598,030 shares having been issued to the vendors of Apoxis. Hereby TopoTarget gains two oncology products to its pipeline. Consistent with the growth strategy pursued by TopoTarget, the acquisition of the Swiss biotech company Apoxis SA shall consolidate two emerging European oncology companies.
 
The two lead oncology products being developed by Apoxis are: APO010, a human FAS-ligand protein product generated via Apoxis' MegaLigandTM proprietary protein research technology platform in Phase I, and APO866, a small molecule therapeutic inhibiting the NAD+ production.